Evidence map›Paper›PMID 40912403›Full record

ReviewMolecular & cellular proteomics : MCP2025

State-of-the-Art and Future Directions in Structural Proteomics.

Lotta J Happonen, Markku Varjosalo

Abstract readReview
In one paragraph

Review in Molecular & cellular proteomics : MCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lotta J HapponenDivision of Infection Medicine, Department of Clinical Sciences Lund, Faculty of Medicine and Science for Life Laboratory, Lund University, Lund, Sweden. Electronic address: lotta.happonen@med.lu.se.
Markku VarjosaloInstitute of Biotechnology, HiLIFE, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Electronic address: markku.varjosalo@helsinki.fi.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Structural proteomics has undergone a profound transformation, driven by the convergence of advanced experimental methodologies and computational innovations. Cutting-edge mass spectrometry (MS)-based approaches, including cross-linking MS (XL-MS), hydrogen-deuterium exchange MS (HDX-MS), and limited proteolysis MS (LiP-MS), now enable unprecedented insights into protein topology, conformational dynamics, and protein-protein interactions. These methods, complemented by affinity purification (AP), co-immunoprecipitation (co-IP), proximity labeling (PL), and spatial proteomics techniques, have expanded our ability to characterize the structural proteome at a systems-wide scale. Integration with electron cryo-microscopy (cryo-EM), cryo-electron tomography (cryo-ET), nuclear magnetic resonance (NMR) spectroscopy, X-ray crystallography, and small-angle X-ray/neutron scattering (SAXS/SANS) methods has further driven the field of integrative structural biology. These methods, in conjunction with AI-driven predictive models such as AlphaFold and RoseTTAFold, enable the high-resolution modeling of protein complexes and dynamic assemblies, bridging the gap between static structures and real-time conformational changes. This review explores the current state-of-the-art in structural proteomics, with a focus on methodological advances and the integration of XL-MS, HDX-MS, and LiP-MS with methods in structural biology. We further discuss the application of structural proteomics in deciphering disease mechanisms, identifying therapeutic targets, and guiding drug discovery, with these techniques poised to revolutionize precision medicine. Future directions emphasize fully integrative, multimodal approaches that unify experimental and computational paradigms, fostering a holistic understanding of the human proteome.

Indexed as

ProteomicsAnimalsHumansMass SpectrometryProtein ConformationHDX-MSintegrated structural biologyLiP-MSsystems structural proteomicsXL-MS

Identifiers

PMID40912403
PMCPMC12546877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.